Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival.
作者信息
Gutterman J U, Richman S P, McBride C M, Burgess M A, Bartold S L, Kennedy A, Gehan E A, Mavligit G, Hersh E M
出版信息
Recent Results Cancer Res. 1978;68:359-62. doi: 10.1007/978-3-642-81332-0_53.
PMID:752870
Abstract
摘要
相似文献
1
Immunotherapy for recurrent malignant melanoma: efficacy of BCG in prolonging the postoperative disease-free interval and survival.复发性恶性黑色素瘤的免疫疗法：卡介苗在延长术后无病间期和生存期方面的疗效。
Recent Results Cancer Res. 1978;68:359-62. doi: 10.1007/978-3-642-81332-0_53.
2
[Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].[皮肤恶性黑色素瘤患者免疫化疗的应用结果]
Chir Ital. 1983 Aug;35(4):519-25.
3
4
Current concepts in the management of malignant melanoma.
Am J Med Sci. 1976 Sep-Oct;272(2):185-95.
5
Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.用卡介苗对人类实体瘤进行免疫治疗：延长恶性黑色素瘤、乳腺癌和结直肠癌的无病间期及生存期。
Ann N Y Acad Sci. 1976;277(00):135-59. doi: 10.1111/j.1749-6632.1976.tb41695.x.
6
Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.复发性恶性黑色素瘤：辅助免疫治疗对生存的影响。
Can Med Assoc J. 1977 Jul 9;117(1):33-6.
7
Mumps virus and BCG vaccine in metastatic melanoma.转移性黑色素瘤中的腮腺炎病毒与卡介苗疫苗
Arch Surg. 1973 Apr;106(4):503-6. doi: 10.1001/archsurg.1973.01350160117019.
8
Adjuvant immunotherapy of malignant melanoma.恶性黑色素瘤的辅助免疫治疗
Cancer. 1979 Apr;43(4):1297-303. doi: 10.1002/1097-0142(197904)43:4<1297::aid-cncr2820430417>3.0.co;2-9.
9
[Immunotherapy of malignant melanoma].[恶性黑色素瘤的免疫治疗]
Harefuah. 1986 Jul;111(1-2):11-7.
10
Results of adjuvant BCG immunotherapy in malignant melanoma.恶性黑色素瘤辅助性卡介苗免疫疗法的结果
Arch Geschwulstforsch. 1981;51(6):493-6.
引用本文的文献
1
Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates.有证据表明用牛痘黑色素瘤细胞裂解物（VMCL）治疗可能会提高II期黑色素瘤患者的生存率。用病毒裂解物治疗II期黑色素瘤。
Cancer Immunol Immunother. 1987;25(3):257-65. doi: 10.1007/BF00199156.
2
The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.II期黑色素瘤患者根治性手术后立即接种卡介苗（BCG）疫苗，皮肤反应性转化对其疗效的意义。
Cancer Immunol Immunother. 1989;28(4):282-6. doi: 10.1007/BF00205238.
Zotero 插件